

1 – 2:15 pm

Migraine Headaches: Tools for Successful Management

SPEAKER
M. Susan Burke, MD, FACP

Presenter Disclosure Information

The following relationships exist related to this presentation:

- M. Susan Burke, FACP, MD: Speakers Bureau for Merck & Co., Inc.

Off-Label/Investigational Discussion

- In accordance with pmiCME policy, faculty have been asked to disclose discussion of unlabeled or unapproved use(s) of drugs or devices during the course of their presentations.

Migraine Headaches: Tools for Successful Management

M. Susan Burke, MD, FACP
Clinical Associate Professor
Sydney Kimmel Medical College of
Thomas Jefferson University

Learning Objectives

- Improve the identification of migraines in the patient with recurring HA and disability.
- Apply the latest evidence-based recommendations for preventive and abortive migraine treatment.
- Recommend complementary and alternative therapies when indicated.

An Old Problem

- Trepanation to relieve headache carried out since 7,000 years BC
- 20-cm long stone chisel used to penetrate skull to relieve pain; some have had multiple procedures done
- Hippocrates wrote specific instructions regarding methods to performing trepanation for headache

<http://www.trepan.com/history.html>. Accessed 5/13/07.

Burden of Disease
A Seven Class Disability Rating System

Disability Class	Severity Weight	Indicator Conditions
1	0.00-0.02	Vitiligo of face, weight for height less than 2 SDs
2	0.02-0.12	Watery diarrhea, severe sore throat, severe anemia
3	0.12-0.24	Radius fracture in a stiff cast, infertility, erectile dysfunction, rheumatoid arthritis, angina
4	0.24-0.36	Below-the-knee amputation, deafness
5	0.36-0.50	Rectovaginal fistula, mild mental retardation, Down syndrome
6	0.50-0.70	Unipolar major depression, blindness, paraplegia
7	0.70-1.00	Active psychosis, dementia, severe migraine, quadriplegia

Menken M, Munsat TL, Toole JF. Arch Neurol. Mar 2000;57:418-420.

Why We Should Care About Migraines?

- They produce severe disability^{1,2}
- Are underdiagnosed and undertreated, often resulting in chronic migraine^{1,2}
- Suboptimal “acute quick-fixes” & overuse of any drug may lead to chronic migraines^{3,4}
- Frequent migraines can produce brain changes, CV morbidity and mortality^{5,6}

1. Lipton RB, et al. *Headache*. 2001;41:646-57. 2. Bigal ME, et al. *Cephalalgia*. 2006;26:43-49. 3. Scher AL, et al. *Pain*. 2003;16:81-89. 4. Bigal ME, Lipton RB. *Headache*. 2006;46:1334-43. 5. Krull, et al. *JAMA* 2004; 291: 427-34. 6. Kurth T, et al. *JAMA*. 2006;296:283-291.

Rita, a 31-year-old mother

- Asks for help with her sinus headaches. She has been getting them for several years but they are occurring almost daily now
- Predominantly frontal and maxillary in location; not throbbing
- Takes acetaminophen almost daily, along with pseudoephedrine preparations and occasional loratadine when she has watery eyes and nasal congestion

What else do you need to know?

Headache Screening: Traditional History Method

Timing/Frequency

- First onset/duration/time of day/relationship to menses

Exacerbating factors/triggers

- Activity, cough, neck position, foods, alcohol, sleep, etc.

Location

- Variable, fixed site, hemicranial

Intensity

- Severity, disability

Nature

- Pulsatile, “ice pick,” steadily increasing

Associated symptoms

- Visual
- Motor
- Sensory
- GI
- Nasal

Diagnosis and Treatment of Headache. Bloomington, MN: Institute for Clinical Systems Improvement (ICSI); 2009.

Headache Screening: Standard Examination

- Observe the patient walking
- Assess symmetry of CN, motor, sensory, coordination, DTRs
- Observe patient’s body language (eye contact, mood)
- Palpate head, arteries, trigger points
- Examine neck for stiffness and ROM
- Perform fundoscopic exam
- Examine oral cavity/TMJ

Diagnosis and Treatment of Headache. Bloomington, MN: Institute for Clinical Systems Improvement (ICSI); 2009.

Red Flags and SSNOOP

- Systemic symptoms: fever, weight loss
- Secondary risk factors: HIV, cancer
- Neurologic symptoms or signs
- Onset: new, sudden, abrupt, or split-second
- Older: especially > 40 years
- Pattern change:
 - Progressive HA with loss of HA-free periods
 - HA changes type or is unclassifiable

Diagnostic testing indicated if any red flags are present

Dodick D. *Adv Stud Med*. 2003;3:87-92.

Green Flags and Comfort Signs

- Stable pattern > 6 mo
- Long-standing HA history
- Family history of similar HA
- Normal exams
- Consistently triggered by
 - Hormonal cycle
 - Specific sensory input
 - Weather changes

Diagnostic testing not indicated if only green flags present

Diagnostic Tests

CT or MRI? With or without contrast?

- **Yield minimal without neurologic signs: < 1% identify cause for HA**
- MRI: greater detail, more false positives
- MRI for posterior fossa disease
- MRI + MRA for suspected aneurysm/other vascular lesions
- CT without contrast to R/O subarachnoid hemorrhage

➤ Weigh radiation exposure with CT, renal contrast concerns with CT and MRI vs. potential yield of study

Ropper A, Brown R, eds. *Adams and Victor's Principles of Neurology*. Eighth ed. New York, NY: McGraw-Hill; 2005:16-21. Avitzur O. *Neurology Today*. 2013;13(4):22-24.

Sinus Headache = Migraine With Sinus Symptoms

Summit ¹	SAMS ²
Self-Diagnosis Sinus Study	Sinus Allergy & Migraine Study
2971 with self-diagnosed recurrent sinus headache	100 with self-diagnosed recurrent sinus headache

86%-88% with self-diagnosis of sinus headache actually have ICHD* migraine or probable migraine headache

***International Conference Headache Disorders/International Headache Classification from International Headache Society (ICS)³**

1. Schreiber CP, et al. *Arch Intern Med*. 2004;164(16):1769-1772.
2. Eross E, et al. *Headache*. 2007;47(2):213-224.
3. International Headache Society. IHS Classification ICHD-II. http://ihs-classification.org/en/02_klassifikation/01_inhalt


Criteria for True "Sinus" Headache

- Major factors
 - Purulence in nasal cavity on exam
 - Facial pain/pressure/congestion
 - Nasal obstruction/blockage/discharge
 - Fever (in acute only)
 - Hyposmia/anosmia
- Minor factors
 - Headache
 - Fever
 - Halitosis
 - Fatigue
 - Dental pain
 - Cough
 - Ear pain/pressure/fullness

American Academy of Otolaryngology– Head and Neck Surgery. Lanza, et al. *Otolaryngol Head Neck Surg*. 1997;117 (pt 2) S1-S7.

HA Prevalence in Primary Care

- Prevalence of all HAs that prompt patients to see their PCP
- Based on expert review of patient HA diaries



Adapted from Tepper SJ, et al. *Headache*. 2004;44(9):856-864.

Recurring moderate to severe headache is migraine until proven otherwise

Migraine Recognition by ICHD Criteria

Migraine without Aura (1.1)

- At least 5 attacks with:
- At least 2 of the following:
 - Unilateral
 - Pulsating
 - Moderate to severe pain
 - Aggravated by or avoidance of routine physical activity
- At least 1 of the following
 - Nausea and/or vomiting
 - Photo and phonophobia
- No organic disease

Migraine with Aura (1.2.1-6)

- At least 2 attacks with:
- At least 1 fully reversible symptom without motor:
 - Visual + and/or -
 - Sensory + and/or -
 - Dysphasic speech
- At least 2 of the following:
 - At least one aura symptom develops gradually over ≥ 5 min or different symptoms occur in succession over ≥ 5 min
 - Each symptom lasts ≥ 5 and ≤ 60 min
 - 1.1 begins with aura or in ≤ 60 min
- No organic disease


ICHD = International Classification of Headache Disorders.
Cephalalgia. 2004;8(suppl 1):S24-26.

International Headache Society Criteria for Chronic Migraine

- HA ≥ 15 days/mo for ≥ 3 months
- Occurring in those with \geq five attacks c/w migraine w/o aura
- On ≥ 8 days per month for ≥ 3 months HA fulfilled C1 and/or C2:
 - Has at least two:
 - unilateral location
 - pulsating quality
 - moderate or severe pain intensity
 - aggravated by/causing to avoid routine physical activities
 - And at least one:
 - nausea and/or vomiting
 - photophobia and phonophobia
 - Treated and relieved by triptan(s) or ergot before expected development of C1 above
- No medication overuse and not attributed to another disorder

http://ihs-classification.org/en/02_klassifikation/05_anhang/01.05.01_anhang.html. Accessed April 22, 2013.

Migraine Pathophysiology: Proposed Mechanisms



Adapted courtesy of Pietron D. *Neuroscientist*. 2005;11:373-386.

Understanding the Patient With Migraine

Commonly reported symptoms at various phases of migraine

<u>Prodrome</u>	<u>Aura*</u>
Fatigue	Scotoma
Cognitive difficulty	Fortification spectrum
Heightened sensory awareness	Paresthesias
Muscle pain	Weakness
Food craving	Vertigo
Fluid retention	Tinnitus
Mood changes	Dysarthria
Anorexia	
Nasal congestion	

*Symptoms utilized by the International Headache Society's diagnostic criteria for migraine

Understanding the Patient With Migraine

Commonly reported symptoms at various phases of migraine (continued)

<u>Mild</u>	<u>Moderate/Severe</u>	<u>Postdrome</u>
Dull headache	Throbbing headache*	Fatigue
Pressure	Headache aggravated by activity*	Anorexia
Mild sensory sensitivity	Nausea*	Poor concentration
Sinus congestion/pressure	Vomiting*	Muscle pain
Muscle pain	Photophobia*	
Anorexia	Phonophobia*	
Fatigue	Osmophobia	
Aura	Fatigue	
	Aura	
	Lacrimation	
	Rhinorrhea	
	Cognitive impairment	

*Symptoms utilized by the International Headache Society's diagnostic criteria for migraine

Migraine-Associated Nausea

- Nausea is the single most important symptom identifier for migraine
- Validated in community-based, college student, neurology clinic and headache clinic
 - Overall sensitivity: 81%
 - Overall specificity: 83%

Martin VT, et al. *Headache*. 2005;45:1102-1112.

Closing the HA Diagnosis Gap *ID Migraine™ – A Validated Screener*

Choose Yes or No

- When you have a HA, do you feel nauseated or sick to your stomach?
- When you have a HA, does light bother you (a lot more than when you don't have a HA)?
- During the last 3 months, have your HAs limited your ability to work, study, or do what you needed to do?

2/3 Yes for migraine:
Sensitivity: 0.81
Specificity: 0.75

= Positive predictive value of
93% in primary care setting

Lipton RB, et al. Neurology. 2003;61(3):375-382.

Closing the HA Diagnosis Gap: POUND Mnemonic

POUND mnemonic useful for the diagnosis of migraine:

- Pulsatile
- One-day duration (episodes lasting 4-72 hours if untreated)
- Unilateral
- Nausea/vomiting
- Disabling

The likelihood ratio (LR) for migraine by the number of POUND criteria:

- 4 of 5 criteria: LR(+) = 24
- 3 of 5 criteria: LR(+) = 3.5
- 2 or fewer criteria: LR(-) = 0.41

Detsky ME, et al. JAMA. 2006;296:1274-1283.

The MIDAS Questionnaire

1 On how many days in the last 3 months did you miss work or school because of your headache ?	Days
2 How many days in the last 3 months was your productivity at work or school reduced by half or more because of your headaches ? (Do not include days you counted in question 1 where you missed work or school)	Days
3 On how many days in the last 3 months did you not do household work because of your headaches ?	Days
4 How many days in the last 3 months was your productivity in household work reduced by half or more because of your headaches ? (Do not include days you counted in question 1 where you did not do household work)	Days
5 On how many days in the last 3 months did you miss family, social, or leisure activities because of your headaches ?	Days
Score: Little or no disability (0-6) → severe disability (21+)	
A On how many days in the last 3 months did you have a headache ? (If a headache lasted more than 1 day, count each day)	Days
B On a scale of 0-10, on average, how painful were these headaches ? (Where 0=no pain at all and 10=pain as bad as it can be)	

Lipton RB, et al. JAMA. 2000;284:2599-2605.

Rethink Your Approach to Headache Complaints

- Ask open ended questions:
 - “Describe your worst headache”
 - If it's a migraine, then *that's* their diagnosis
 - Don't think they have different HAs like sinus, tension *and* migraine
 - “How do you feel between headaches?”
 - If not normal, they likely have a migraine and may also have transformed or have chronic migraine
- Use a migraine screener, then move forward with treatment plan

Clinical Pearls

- Migraine patients can experience many different types of HAs from the same underlying mechanism
- Prompt treatment may restore normal neurologic function and prevent the evolution of episodic to chronic HA

Principles of Migraine Management

- Establish realistic expectations
 - ≈50% reduction with prevention
 - ≥70% relief with acute treatment
- **THERE IS NO “CURE”!**

Principles of Management for the Patient

- Encourage patients to participate in their care
 - Accept that some Rx side effects are inevitable
 - Optimize behavioral management
 - Acute: Treat early, ≤ 2 days/week or 9 days/mo.
 - Prevention: follow guidelines for drug/complementary/alternative treatments
 - Regular patient follow-up with dose/drug/combination changes as needed

Roger, a 31-year-old CPA

- Has history of very occasional migraines since his early twenties which he manages with a triptan
- Started new job 6 months ago, requiring him to work long hours
- Headaches have increased and now occur on most weekend days for the last few months

What might be contributing to the increase in his headaches?

Behavioral Strategies

1. **Sleep** – 6 to 8 hours, consistent within 1 hour to bed/rise (even weekends!)
2. **Exercise** – Any better than none; aerobic >> nonaerobic
3. **Stress management**– Biofeedback/relaxation, cognitive-behavioral, time management
4. **↓ Substance use** – Taper caffeine to maximum 1-6 oz cup – Eliminate artificial sweeteners, decongestants, smoking
5. **Eat** – Fresh, non-processed, small, frequent healthy meals/snacks

Headache Diary and Calendar

- Have patient note HA characteristics, including intensity, timing, duration, triggers and medications used
- Consider withdrawal of all processed foods for 1-2 weeks; if HAs are better, reintroduce individual additives slowly

Management of Migraine with Behavioral Strategies

Evidence-based Medicine Specific Treatment Recommendations

- ✓ All types: eg, relaxation, EMG biofeedback, cognitive behavioral therapy - may be considered as treatment options for prevention (Grade A)
- ✓ Behavioral therapy combined with preventive drug therapy achieves additional improvement (Grade B)

Courtesy of Donald Penzien, PhD, US Headache Consortium Guidelines, 2000.
www.aan.com/professionals/practice/pdfs/g0089.pdf. Accessed March 21, 2009.

Abortive Treatments

- Administer early, rapidly, and consistently– ideally within 15 minutes
 - Minimizes use of backup and rescue medication
- Consider formulation (route, onset, duration of action) based on symptoms
- Note: can't "cure" every HA with "quick fixes"
 - Takes time, patience, and follow-up
- Avoid both under treatment and overtreatment with acute medications

Cady R, et al. Headache. 2004;44:426-435.

Abortive Agents: General Principles

- Treat 2-3 attacks with agent to assess efficacy
 - If little success, consider:
 - Different agent or route in same class
 - Adding co-therapy
 - Switching to different class
- *Use abortive agent no more than*
 - 2-3 days/week
 - 9 days/month
 - 12-15 doses/month *of anything*

Evidence-Based Guidelines for Migraine Headache in the Primary Care Setting: Pharmacological Management of Acute Attacks. <http://www.aan.com/professionals/practice/pdfs/g0087.pdf>. Accessed December 17, 2007.

Abortive Agents

Evidence-based guidelines adopted by AAFP, ACP-ASIM, and AAN

- **First line: NSAIDs**
- Triptans (or dihydroergotamine) for NSAID intolerance/unresponsiveness
- No evidence for butalbital compounds in migraine
- Little evidence for isometheptene compounds
- Opioids "reserved for use when others cannot be used"
 - May worsen central sensitization; should be avoided
- Metoclopramide recommended for oral therapies as prokinetic if gastric stasis present*

AAFP = American Academy of Family Physicians, ACP-ASIM = American College of Physicians-American Society of Internal Medicine, AAN = American Academy of Neurology.
* European Headache Federation recommendation

Snow V, et al. *Ann Int Med*. 2002;137:840-849; Jakubowski M, et al. *Headache*. 2005;45:850-861.

Triptan Selection

- Start with formulary agent; generics available for some
- Chose formulation: oral, wafer, nasal, SC, based on symptoms or HA presentation
 - Oral formulations more alike than different
 - Use early when HA still mild, if possible
 - Optimize dose (typically maximum)
- Avoid if ≥ 3 cardiac risk factors, uncontrolled hypertension, severe liver disease

SC = subcutaneous

Dodick D, et al. *Headache*. 2004;44:414-425.

Combination Abortive Therapies

- Consider drugs which may complement each other
 - Triptan + NSAID
 - Acetaminophen/ASA/caffeine
 - NSAID + caffeine
 - Metoclopramide + triptan *or* NSAID *or* ASA
- Tailor to coincident symptoms

Silberstein SD, et al. *Postgrad Med*. 2006; Apr.; Spec No: 20-6.

Migraine Prevention

Many patients qualify,
few are chosen....

**...Offer preventive
treatment early**

Guidelines for Initiating Migraine Prevention Therapy

- ≥ 2 attacks/mo with disability totaling >3 d/mo
- Recurring HA significantly interfering with patient's daily routine despite acute Rx
- Acute medications overused >2 d/wk, ineffective, intolerable side effects, or contraindicated
- Presence of uncommon migraine conditions: hemiplegic migraine, prolonged aura
- Patient preference, cost considerations or intolerance to acute agents

Ramadan NM. Evidence-based guidelines. <http://www.aan.com>. Accessed December 18, 2007; Silberstein SD, et al. *Wolff's Headache and Other Head Pain*. 2003.

Goals of Prevention

1. Fewer HAs
 - Best expectation: 50% reduction in ~50% of HAs
2. More/better response to acute “quick fix” drugs
 - Reduced HA impact (duration, intensity, symptoms)
3. Restoration of function
 - Less disability related to work/family/home activities


Silberstein SD. *Curr Opin Neurol*. 2005;18:289–292.

Medication-Overuse Headache (Formerly Rebound Headache)

- A pharmacologically maintained HA
- >15 d/mo with HA
- Regular acute drug use >10 d/mo (>15 d for simple analgesics) for >3 mo
- HA worsens over time of overuse
- HA resolves or reverts to previous pattern within 2 mo of overuse elimination

http://www.americanheadachesociety.org/assets/1/7/Stephen_Silberstein_-_Medication_Overuse_Headache.pdf
Accessed April 7, 2013.

Medication Overuse Headache Hierarchy of Common Culprits




Bigal ME, et al. *Cephalalgia*. 2004;24:483–490.

Prevention Opportunities

- Preventive treatment can be:
 - Preemptive or prodromal (eg, migraine induced by exercise—use indomethacin 1-2 h prior to exercise but don't overuse!)
 - Short-term or cyclic (eg, air travel or menstrual related—NSAID, triptan, or hormonal intervention)
 - Long-term (eg, >8-9 d/mo with HA; control for 12 mo)

Lane, JC. *Semin Neurol*. 2000;20:195–200.

Prevention: General Concepts



Silberstein, SD et al. *Headache in Clinical Practice*. 2nd ed. 2002.

Migraine Preventive Therapies US Classification and Level of Evidence

Level A: Medications with *established* efficacy*

- **Antiepileptic drugs**
 - Divalproex sodium
 - Sodium valproate
 - Topiramate
- **Beta blockers**
 - Metoprolol
 - Propranolol
 - Timolol
- **Triptans**
 - Frovatriptan (for menstrual-related migraine)

* in ≥ 2 Class I Trials

Not all agents are approved for migraine prevention

Silberstein SD, et al. *Neurology* 2012;78:1337–1345.

Migraine Preventive Therapies US Classification and Level of Evidence

Level B: Medications which are *probably* effective*

- | | |
|--|--|
| <ul style="list-style-type: none"> – Antidepressants/SSRI/SSNRI/TCA <ul style="list-style-type: none"> • Amitriptyline • Venlafaxine – Beta blockers <ul style="list-style-type: none"> • Atenolol • Nadolol | <ul style="list-style-type: none"> – Triptans <ul style="list-style-type: none"> • Naratriptan • Zolmitriptan <p>(for menstrual-related migraine)</p> |
|--|--|

* in 1 Class I or 2 Class II studies

Not all agents are approved for migraine prevention

Silberstein SD, et al. *Neurology* 2012;78:1337-1345.

Migraine Preventive Therapies US Classification and Level of Evidence

Level C: Medications which are *possibly* effective*

- | | |
|--|---|
| <ul style="list-style-type: none"> – ACE inhibitors <ul style="list-style-type: none"> • Lisinopril – Angiotensin receptor blockers <ul style="list-style-type: none"> • Candesartan – Alpha agonists <ul style="list-style-type: none"> • Clonidine • Guanfacine | <ul style="list-style-type: none"> – Antiepileptic drugs <ul style="list-style-type: none"> • Carbamazepine – Beta blockers <ul style="list-style-type: none"> • Nebivolol • Pindolol – Antihistamines <ul style="list-style-type: none"> • Cyproheptadine |
|--|---|

* in 1 Class II Study

Not approved for migraine prevention

Silberstein SD, et al. *Neurology* 2012;78:1337-1345.

Migraine Preventive Therapies US Classification and Level of Evidence

Agents with *inadequate* data or *probably* ineffective

- | | |
|--|---|
| <p>Inadequate Data</p> <ul style="list-style-type: none"> – Verapamil – Nifedipine – Fluoxetine – Acetazolamide – Gabapentin | <p>Probably Ineffective</p> <ul style="list-style-type: none"> – Lamotrigine – Oxcarbazepine – Clonazepam – Nabumatone – Telemisartan |
|--|---|

Not approved for migraine prevention

Silberstein SD, et al. *Neurology* 2012;78:1337-1345.

Selection of Prevention Medication

Consider patient comorbidities

- Beta blockers
 - Hypertension, angina
- Anticonvulsants
 - Seizures, mood disorders (valproate), obesity (topiramate)
- Antidepressants
 - Underweight, trouble sleeping, depression

Migraines and Pregnancy

- 50%–80% of migraineurs note decreased HA frequency after 1st trimester
- New-onset migraines in pregnancy warrant workup to r/o secondary causes
- Optimize trigger management and nonpharmacologic treatments
 - Massage, relaxation
- Acetaminophen, metoclopramide, (NSAIDs before third trimester), triptans
- If prevention is needed, use category C drugs if benefits outweigh risks*
 - propranolol – verapamil – ?magnesium?

Tozer BS, et al. *Mayo Clin Proc*. August 2006;81:1086-1092
<http://www.aafp.org/aafp/2011/0201/a271.pdf>. Accessed April 22, 2013.

NSAIDs/Complementary Treatments for Migraine Prevention: Level of Evidence

Level A: Established efficacy

- Butterbur (*Petasites hybridus*)

Level B: Probable efficacy

- NSAIDs - ibuprofen, naproxen, fenoprofen, ketoprofen
- Herbal, vitamins, minerals, other
 - Magnesium, riboflavin, MIG-99 (feverfew), histamine SC

Level C: Possible efficacy

- NSAIDs – flurbiprofen, mefenamic acid
- Herbal, vitamins, minerals, other
 - Co-enzyme Q10, estrogen

Not approved for migraine prevention

Holland S, et al. *Neurology*. April 24, 2012;78 (17):1346-1353.

Commonly Used Alternative Therapies

- Butterbur (petasite): 50-75 mg BID
- Oral magnesium: 400-600 mg/d
- Vitamin B₂ (riboflavin): 400 mg/d
- Feverfew: No standardized preparations
- NSAIDs: naproxen 500 mg BID and others
- Co-enzyme Q-10: 100 mg TID effective in small trial

<http://www.neurology.org/content/78/17/1346.full.pdf+html>. Accessed March 10, 2013.

Acupuncture

- Appears effective for migraine prophylaxis
 - May be slightly better than pharmacotherapy
 - Sham just as effective as real
 - Strength of Recommendation = A

<http://summaries.cochrane.org/CD001218/acupuncture-for-migraine-prophylaxis>. Accessed March 10, 2013.

Osteopathic or Spinal Manual Therapy (OMT or SMT)

- Studies suggest spinal, or osteopathic manipulation may be beneficial for migraines¹
 - Studies difficult to standardize and randomize due to varying nature and presentations of migraine headaches
- Head to head trial in 218 patients for prophylaxis of migraines²:
 - 8 wks of amitriptyline vs SMT had equivalent efficacy
 - Efficacy not better with combination
 - Efficacy better in SMT group 4 wks after both therapies stopped
 - SMT better tolerated than amitriptyline

1. Bronfort G, et al. J Manipulative Physiol Ther. 2001;24(7):457-66
2. Nelson CF et al. J Manipulative Physiol Ther. 1998;21(8):511-9

Additional Alternative Considerations

- Exercise
- Yoga
- Tai Chi
- Homeopathy
- Hypnotherapy
- Cold therapy
- Massage
- Physical therapy

Chronic Migraine Treatment

- OnabotulinumtoxinA (botox)
 - Approved for prophylaxis of chronic migraine (≥ 15 headache days/month)
 - 8-9 fewer HA compared to 6-7 with placebo
 - 31 injection sites into head/neck Q 3 mo.
 - Boxed warning re: possibility for spread causing weakness in distant area(s)

http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103000s5251b1.pdf

Summary

- **Recurring HA with disability is migraine until proven otherwise**
- Both clinician and patient must have realistic expectations
- Use of acute meds > 9 days/month can lead to medication overuse
 - Avoid opiate and barbiturate use
- Chronic migraines can be reduced with prevention strategies, so
- Offer preventive treatment early